JanOne Inc. announced the addition of Douglas Flanagan, PhD as the company's chief formulation advisor. Dr. Flanagan will work directly with CoreRX, JanOne's manufacturing partner to ensure the integrity of TV1001SR, the company's clinical candidate for treating Peripheral Artery Disease (PAD) expected soon to enter phase 2 trials. He will also play an integral role for the potential identification and advancement of other clinical candidates to treat pain as the company hopes to broaden its pipeline in the near future. Dr. Flanagan brings over 40 years of scientific, pharmaceutical formulation and clinical experience and has published over 90 peer reviewed articles and delivered over 150 presentations, talks and lectures around the world. He has lent his formulation expertise to over 50 pharmaceutical companies and medical organizations including Abbott Laboratories, Pfizer Animal Health (spun off as Zoetis), Bristol Myers Squibb, the World Health Organization and the Federal Drug Administration(FDA) to name a few.